Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Arcturus TherapeuticsNorthwest BiotherapeuticsPliant TherapeuticsZogenixOmeros
SymbolNASDAQ:ARCTOTCMKTS:NWBONASDAQ:PLRXNASDAQ:ZGNXNASDAQ:OMER
Price Information
Current Price$36.64$1.40$28.18$18.80$18.55
52 Week RangeHoldN/ABuyBuyBuy
MarketRank™
Overall Score1.60.52.01.71.4
Analysis Score3.10.03.53.43.3
Community Score2.62.74.62.82.9
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.70.8
Earnings & Valuation Score0.60.00.00.60.0
Analyst Ratings
Consensus RecommendationHoldN/ABuyBuyBuy
Consensus Price Target$70.67N/A$46.60$58.25$23.40
% Upside from Price Target92.87% upsideN/A65.37% upside209.84% upside26.15% upside
Trade Information
Market Cap$962.90 million$1.18 billion$1.01 billion$1.05 billion$1.15 billion
Beta3.010.93N/A1.61.65
Average Volume1,179,0342,235,888165,721824,200732,646
Sales & Book Value
Annual Revenue$20.79 million$2.41 million$57.05 million$3.65 million$111.81 million
Price / Sales46.32489.6917.65287.4810.28
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.70 per share($0.07) per shareN/A$5.54 per share($2.19) per share
Price / Book21.55-20.003.39-8.47
Profitability
Net Income$-25,990,000.00$-20,300,000.00$-630,000.00$-419,500,000.00$-84,490,000.00
EPS($2.15)N/AN/A($3.90)($0.96)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-506.70%-2,658.66%20.83%-8,758.48%-134.59%
Return on Equity (ROE)-52.32%N/A16.55%-53.91%N/A
Return on Assets (ROA)-33.21%-47.19%8.33%-36.49%-59.49%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.06%N/AN/AN/AN/A
Current Ratio11.21%0.09%27.91%4.58%4.11%
Quick Ratio11.21%0.09%27.91%4.58%4.07%
Ownership Information
Institutional Ownership Percentage74.33%0.02%79.46%96.57%56.63%
Insider Ownership Percentage12.60%21.30%N/A3.50%11.30%
Miscellaneous
Employees1181770218277
Shares Outstanding26.28 million842.97 million35.74 million55.81 million61.93 million
Next Earnings Date5/6/2021 (Estimated)6/23/2021 (Estimated)6/15/2021 (Estimated)5/4/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
Global PNH and aHUS Market 2020 Coronavirus (COVID-19) Updated Analysis By Key Players Omeros Corporation, RA Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals - Clark County BlogGlobal PNH and aHUS Market 2020 Coronavirus (COVID-19) Updated Analysis By Key Players Omeros Corporation, RA Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals - Clark County Blog
clarkcountyblog.com - April 19 at 3:37 PM
Omeros Stock Is Estimated To Be Modestly Overvalued - Yahoo FinanceOmeros Stock Is Estimated To Be Modestly Overvalued - Yahoo Finance
finance.yahoo.com - April 19 at 3:37 PM
Omeros Stock Is Estimated To Be Modestly Overvalued - GuruFocus.comOmeros Stock Is Estimated To Be Modestly Overvalued - GuruFocus.com
gurufocus.com - April 19 at 10:36 AM
Omeros: The Prize Is Nigh - Seeking AlphaOmeros: The Prize Is Nigh - Seeking Alpha
seekingalpha.com - April 19 at 10:36 AM
Omeros Stock Is Estimated To Be Modestly OvervaluedOmeros Stock Is Estimated To Be Modestly Overvalued
gurufocus.com - April 19 at 6:10 AM
Omeros: The Prize Is NighOmeros: The Prize Is Nigh
seekingalpha.com - April 18 at 11:47 PM
Zacks: Analysts Anticipate Omeros Co. (NASDAQ:OMER) to Announce -$0.49 EPSZacks: Analysts Anticipate Omeros Co. (NASDAQ:OMER) to Announce -$0.49 EPS
americanbankingnews.com - April 15 at 6:20 PM
Omeros Co. (NASDAQ:OMER) Given Average Recommendation of "Buy" by BrokeragesOmeros Co. (NASDAQ:OMER) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 15 at 10:48 AM
Omeros Corp (OMER) CHAIRMAN, CEO & PRESIDENT Gregory A Md Demopulos Sold $1.3 million of Shares - Yahoo FinanceOmeros Corp (OMER) CHAIRMAN, CEO & PRESIDENT Gregory A Md Demopulos Sold $1.3 million of Shares - Yahoo Finance
finance.yahoo.com - April 9 at 12:33 AM
Omeros Co. (NASDAQ:OMER) CEO Gregory A. Md Demopulos Sells 72,613 SharesOmeros Co. (NASDAQ:OMER) CEO Gregory A. Md Demopulos Sells 72,613 Shares
americanbankingnews.com - April 8 at 10:14 PM
Omeros Corp (OMER) CHAIRMAN, CEO & PRESIDENT Gregory A Md Demopulos Sold $1.3 million of SharesOmeros Corp (OMER) CHAIRMAN, CEO & PRESIDENT Gregory A Md Demopulos Sold $1.3 million of Shares
gurufocus.com - April 8 at 8:39 PM
Omeros on the Beach restaurant at Ramsgate Beach permanently closes after almost 20 years - Greek Herald'Omeros on the Beach' restaurant at Ramsgate Beach permanently closes after almost 20 years - Greek Herald
greekherald.com.au - April 7 at 10:25 PM
Omeros on the Beach at Ramsgate Beach shuts its doors - St George and Sutherland Shire LeaderOmeros on the Beach at Ramsgate Beach shuts its doors - St George and Sutherland Shire Leader
theleader.com.au - April 6 at 12:40 AM
Ischemia Reperfusion Injury Therapeutics Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- Nyken BV, Omeros Corporation, Opsona Therapeutics Limited, Orexo AB, Pharming Group NV, etc. - The Market EagleIschemia Reperfusion Injury Therapeutics Market 2021 Is Rapidly Increasing Worldwide in Near Future | Top Companies Analysis- Nyken BV, Omeros Corporation, Opsona Therapeutics Limited, Orexo AB, Pharming Group NV, etc. - The Market Eagle
themarketeagle.com - March 30 at 2:52 PM
Analysts Say Omeros Corporation (NASDAQ:OMER) Can Really Get to $34 in 12 MonthsAnalysts Say Omeros Corporation (NASDAQ:OMER) Can Really Get to $34 in 12 Months
marketingsentinel.com - March 27 at 9:28 PM
IBD Rating Upgrades: Omeros Shows Improved Technical Strength - Investors Business DailyIBD Rating Upgrades: Omeros Shows Improved Technical Strength - Investor's Business Daily
investors.com - March 24 at 5:33 PM
Omeros Says First Patients Dosed With Narsoplimab In I-SPY COVID-19 TrialOmeros Says First Patients Dosed With Narsoplimab In I-SPY COVID-19 Trial
markets.businessinsider.com - March 24 at 7:31 AM
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 TrialOmeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
finance.yahoo.com - March 23 at 10:15 AM
First Week of OMER November 19th Options Trading - NasdaqFirst Week of OMER November 19th Options Trading - Nasdaq
nasdaq.com - March 22 at 2:10 PM
Analyst Rating: Will Omeros Corporation (OMER) Stock Beat the Market? - InvestorsObserverAnalyst Rating: Will Omeros Corporation (OMER) Stock Beat the Market? - InvestorsObserver
investorsobserver.com - March 19 at 3:34 PM
Omeros price target raised at BofA on expert views for narsoplimab - Seeking AlphaOmeros price target raised at BofA on expert views for narsoplimab - Seeking Alpha
seekingalpha.com - March 15 at 10:39 PM
IBD Rating Upgrades: Omeros Flashes Improved Price Strength - Investors Business DailyIBD Rating Upgrades: Omeros Flashes Improved Price Strength - Investor's Business Daily
investors.com - March 15 at 5:39 PM
Stock Upgrades: Omeros Shows Rising Relative Strength - Investors Business DailyStock Upgrades: Omeros Shows Rising Relative Strength - Investor's Business Daily
investors.com - March 8 at 12:39 PM
Dave Stewart and Joss Stone Write New Musical THE TIME TRAVELLERS WIFEDave Stewart and Joss Stone Write New Musical THE TIME TRAVELLER'S WIFE
broadwayworld.com - March 5 at 5:32 PM
Edited Transcript of OMER.OQ earnings conference call or presentation 1-Mar-21 9:30pm GMT - Yahoo FinanceEdited Transcript of OMER.OQ earnings conference call or presentation 1-Mar-21 9:30pm GMT - Yahoo Finance
finance.yahoo.com - March 2 at 12:49 PM
DateCompanyBrokerageAction
3/8/2021Arcturus TherapeuticsB. RileyLower Price Target
3/2/2021Arcturus TherapeuticsRoth CapitalLower Price Target
1/7/2021Arcturus TherapeuticsWells Fargo & CompanyInitiated Coverage
12/29/2020Arcturus TherapeuticsHC WainwrightDowngrade
12/29/2020Arcturus TherapeuticsRobert W. BairdDowngrade
12/29/2020Arcturus TherapeuticsBarclaysDowngrade
12/29/2020Arcturus TherapeuticsRaymond JamesDowngrade
12/14/2020Arcturus TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/14/2020Arcturus TherapeuticsSmith Barney CitigroupBoost Price Target
8/25/2020Arcturus TherapeuticsPiper SandlerInitiated Coverage
8/11/2020Arcturus TherapeuticsBrookline Capital ManagementReiterated Rating
5/29/2018Northwest BiotherapeuticsS&P Equity ResearchLower Price Target
4/20/2021Pliant TherapeuticsBTIG ResearchInitiated Coverage
8/12/2020Pliant TherapeuticsNeedham & Company LLCReiterated Rating
6/29/2020Pliant TherapeuticsCowenInitiated Coverage
12/2/2020ZogenixMizuhoReiterated Rating
8/6/2020ZogenixNorthland SecuritiesReiterated Rating
6/26/2020ZogenixWilliam BlairReiterated Rating
2/28/2020ZogenixLADENBURG THALM/SH SHReiterated Rating
2/14/2020ZogenixStifel NicolausReiterated Rating
1/21/2020ZogenixGuggenheimReiterated Rating
12/6/2019ZogenixPiper Jaffray CompaniesReiterated Rating
2/1/2021OmerosUBS GroupInitiated Coverage
12/4/2020OmerosMaxim GroupBoost Price Target
10/20/2020OmerosBank of AmericaInitiated Coverage
9/1/2020OmerosWedbushLower Price Target
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.